The PD-1/PD-L1 checkpoint and the CTLA4 checkpoint are the most extensively studied targets for more efficacious and precise cancer immunotherapy, especially in non-small-cell lung cancer (NSCLC) [106,107]. Here, CTLA4 is linked to cancer.